September 4, 2025 4:50pm

As the market and employment data randomization of sector’s share pricing

After I wrote this a.m., “Time to reap the share pricing fruit … There's also a case for taking partial profits in stronger names rather than waiting for them to buckle”

News: Sangamo Therapeutics (SGMO -$0.0038 to $0.53) detailed data from the registrational P1/2 STAAR study evaluated isaralgagene civaparvovec, or ST-920, an investigational gene therapy for the treatment of adults with Fabry disease. The ability for patients to discontinue the use of burdensome enzyme replacement therapies further supports the potential of ST-920 as a single-dose, durable treatment option for people living with Fabry disease.

Remember, “The sector is what it is, until it isn’t, even if it doesn’t seem to be, it yet will be.”  Never leave an investor uninformed!  

I answer or qualify the sector’s equity’s movement; with an emphasis on which company is gaining or losing stride in your portfolio for the short-term

 

Thursday’s RegMed Investors’ (RMi) pre-open: Time to reap the share pricing fruit … https://www.regmedinvestors.com/articles/14091

RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB): Just another wrinkle – Q2/25’s 10-Q – liabilities exceed cash position … https://www.regmedinvestors.com/articles/13812

 

Thursday: The Dow closed UP +350.06 points or +0.77%, the S&P closed UP +53.82 points or +0.83% while the Nasdaq closed UP +209.968 points or +0.98%

  • Theme of the session, weak private payrolls data raised the stakes for Friday’s official jobs report

Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy

  •  The ADP private payrolls report showed an increase of 54 K in August. Economists had expected private employers to add 75 K jobs. The figure is also less than the revised 106 K in July.
  • Jobless (unemployment) claims for the week ended Aug. 30 also increased to 237 K; coming in above estimates and marked an 8 K gain from the prior week.
  • August’s ISM non-manufacturing PMI reading came in at 52.0, slightly better than the forecast for 50.8.

Thursday’s my 40 covered sector’s advance/decline line opened negative with 14 incliners, 24 decliners and 2 flats ending with a negative close of 17 incliners, 21 decliners and 2 flats

Metrics:  Thursday, the IBB was down -0.01%, the XBI was down -0.18% while the VIX was down -0.95 points or -5.81% at 15.40

 

Q3 – 1 holiday, 1 negative and 2 positive closes

  • August – 12 negative and 9 positive closes
  • July – 1 market holiday, 13 positive and 9 negative closes

 

Thursday Closing UP (10 of 19) after Monday’s holiday

  • Alnylam Pharmaceuticals (ALNY +$6.11 after Wednesday’s +$0.43 and Tuesday’s +$0.49),
  • BioNTech SE (BNTX +$3.08 after Wednesday’s -$0.20 and Tuesday’s +$0.62),
  • BioLife Solutions (BLFS +$0.83 after Wednesday’s -$0.30 and Tuesday’s +$0.29),
  • Lenz Therapeutics (LENZ +$0.65),
  • Mesoblast (MESO +$0.64 after Wednesday’s -$0.24),
  • Supernus Therapeutics (SUPN +$0.50 after Wednesday’s +$0.39 and Tuesday’s -$0.58)
  • uniQure NV (QURE +$0.35 after Wednesday’s +$0.37 and Tuesday’s +$0.68),
  • Vertex Pharmaceuticals (VRTX +$0.31 after Wednesday’s -$4.38 and Tuesday’s +$9.98),
  • Moderna (MRNA +$0.23 after Wednesday’s -$0.14),
  • Arrowhead Pharmaceuticals (ARWR +$0.20 after Wednesday’s +$2.12 and Tuesday’s +$3.65),

Flat (2)

  • Compass Therapeutics (CMPX)
  • Harvard Apparatus RT (OTCQB: HRGN)

Wednesday’s Closing DOWN (10 of 21): after Monday’s holiday

  • Ionis Pharmaceuticals (IONS -$1.14 after Wednesday’s +$3.00 and Tuesday’s +$14.86),
  • IQV Holdings (IQV -$0.45 after Wednesday’s +$0.90 after Tuesday’s - $3.07),
  • Sarepta Therapeutics (SRPT -$0.49 after Wednesday’s +$0.79),
  • Regenxbio (RGNX -$0.43 after Wednesday’s +$0.74),
  • Capricor Therapeutics (CAPR -$0.34),
  • CRISPR Therapeutics (CRSP -$0.24),
  • Ultragenyx Pharmaceuticals (RARE -$0.27 after Wednesday’s -$0.48 and Tuesday’s +$2.07),
  • Beam Therapeutics (BEAM -$0.22 after Wednesday’s +$2.34 and Tuesday’s -$0.05),
  • AxoGen (AXGN -$0.21 after Wednesday’s -$0.10 and Tuesday’s -$0.43),
  • Generation Bio (GBIO -$0.20),

 

The BOTTOM LINE:  More of the … WHYs …

Thursday’s stock market action featured strong breadth all day.

  • Indexes stumbled at the start before picking up steam as the session rolled on.
  • While the cell and gene therapy sector started with a negative open that continued to lose momentum as the session moved-on to a negative close.

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”
  • Yet, I was again on target … this 5 a.m.

The S&P 500 closed at a record on Thursday after the latest wave of labor market data cemented bets on a September rate cut with a major August nonfarm payrolls report on tap. <Barron’s>

The Nasdaq advanced 1%; while small caps on the Russell 2000 also powered up 1%.

  • Volume was modestly lower on the Nasdaq compared with Wednesday.
  • While the 10-year Treasury yield dropped to 4.19%.
  • The yield on the 2-year Treasury note dropped to 3.59%. The 10-year yield dropped to 4.18%. <IBD>

August nonfarm payrolls report will be the more important datapoint.

  • “In the short term, markets may embrace that data because it should increase the odds of Fed rate cuts. But if the numbers deteriorate too much, it could raise concerns about the health of the economy.” < Chris Larkin, managing director, trading and investing at E*TRADE from Morgan Stanley>

Cell and gene therapy sector equities closed negative on Thursday after Wednesday’s positive after Tuesday’s positive close …

 

September: understand the “flow” …

  • 9/4 – Thursday closed negative with 17 positive, 21 negative and 2 flats of 40 covered
  • 9/3 - Wednesday closed positive with 22 positive, 16 negative and 2 flats
  • 9/2 -Tuesday closed positive with 22 positive, 18 negative and 0 flat
  • 9/1 -Monday was a holiday

August’s final week:

  • 8/29 – Friday closed negative with 7 positive, 27 negative and 1 flat of 35 covered
  • 8/28 – Thursday closed negative with 15 positive, 17 negative and 3 flats
  • 8/27 – Wednesday closed negative with 16 positive, 17 negative and 2 flats
  • 8/26 – Tuesday closed positive with 25 positive, 9 negative and 1 flat
  • 8/25 – Monday closed negative with 4 positive, 29 negative and 2 flats

 

“I hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

  • If I have learned one thing as a former research analyst in a venture and public fund, operating executive, x-FBI, x-military officer and an adjunct (MBA) business school professor now a journalist; my life and your portfolio are largely tied to knowledge of price movements and questioning pricing targets and more.
  • I was once told by a “very” prominent figure early in my career, “write it right, keep it tight without hype and never lose the stride to guide the reader” – they were pretty simple instructions to follow!

 

Why do I keep repeating, so investors can make the connection …

The top three (3) performing in the session:   

  • Thursday: Alnylam Pharmaceuticals (ALNY), BioNTech (BNTX) and BioLife Solutions (BLFS)
  • Wednesday: Ionis Pharmaceuticals IONS), Beam Therapeutics (BEAM) and Arrow Pharmaceuticals (ARWR)
  • Tuesday: Ionis Pharmaceuticals IONS), Vertex Pharmaceuticals (VRTX) and Arrow Pharmaceuticals (ARWR)
  • Monday was a holiday
  • Friday: IQVIA Holdings (IQV), Lenz Therapeutics (LENZ) and Vericel (VCEL)

The worst three (3) in the session: 

  • Thursday: Ionis Pharmaceuticals IONS), IQVIA Holdings (IQV) and Sarepta Therapeutics (SRPT)
  • Wednesday: Vertex Pharmaceuticals (VRTX), wave Life Sciences (WVE) and Vericel (VCEL)
  • Tuesday: IQVIA Holdings (IQV), Vericel (VCEL) and Mesoblast (MESO)
  • Monday was a holiday
  • Friday: Alnylam Pharmaceuticals (ALNY), Mesoblast (MESO) and BioNTech (BNTX)

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.